Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company.
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.
- 1 “Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab” (PDF). American Medical Association.
- 2 http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx
|Molar mass||146.25 kg/mol|
////////////タバルマブ , 遺伝子組換え, Tabalumab, 1143503-67-6, antibody, Monoclonal antibody